Company intelligence / Profile preview

Biocon

Bangalore, Karnataka, Indiabiocon.com ↗

Ownership: Public · BIOCON
Employees: ~12000
Development stage: Commercial

Overview

Biocon has successfully commercialized several first-in-world biosimilars approved by US FDA including trastuzumab, pegfilgrastim, glargine insulin. It supplies over ~7.3 billion doses of insulin globally since inception. Their portfolio includes around 20 biosimilars with at least nine commercialized worldwide. The company focuses on affordable access to biologic therapies especially in diabetes and oncology[1][2][5][6].

Therapeutic areas: OncologyEndocrinologyImmunology
Modalities: BiosimilarsRecombinant human insulin and insulin analogsSmall molecules (APIs)Complex biologicsMonoclonal antibodies (mAbs)
Industry: Biotech

Drug pipeline

9 assets

itolizumab

8 more assets in the full pipeline.

Request access →

Financials

Market cap: $6.9B
Total revenue: $2.6B
Enterprise value: $8.7B

Beyond the preview

Go deeper on Biocon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biocon.

Explore the full profile